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Monitoring changes in circulating tumour cells as
a prognostic indicator of overall survival and
treatment response in patients with metastatic
melanoma
Dragana Klinac1, Elin S Gray1*, James B Freeman1, Anna Reid1, Samantha Bowyer2, Michael Millward2,3
and Melanie Ziman1,4

Abstract
Background: New effective treatments for metastatic melanoma greatly improve survival in a proportion of
patients. However biomarkers to identify patients that are more likely to benefit from a particular treatment are
needed. We previously reported on a multimarker approach for the detection of heterogenous melanoma
circulating tumour cells (CTCs). Here we evaluated the prognostic value of this multimarker quantification of CTCs
and investigated whether changes in CTC levels during therapy can be used as a biomarker of treatment response
and survival outcomes.
Methods: CTCs were captured by targeting the melanoma associated markers MCSP and MCAM as well as the
melanoma stem cell markers ABCB5 and CD271. CTCs were quantified in 27 metastatic melanoma patients treated
by surgery or with vemurafenib, ipilimumab or dacarbazine. Patients were enrolled prospectively and CTC counts
performed at baseline (prior to treatment), during and after treatment.
Results: Baseline CTC numbers were not found to be prognostic of overall survival nor of progression free survival.
However, a low baseline CTC number was associated with a rapid response to vemurafenib therapy. A decrease in
CTCs after treatment initiation was associated with response to treatment and prolonged overall survival in
vemurafenib treated patients.
Conclusions: Measuring changes in CTC numbers during treatment is useful for monitoring therapy response in
melanoma patients and for providing prognostic information relating to overall survival. Further studies with larger
sample sizes are required to confirm the utility of CTC quantification as a companion diagnostic for metastatic
melanoma treatment.
Keywords: Circulating tumour cells, Melanoma, Vemurafenib

Background
The prognosis for patients with metastatic melanoma
has improved significantly over the last three years with
the implementation of novel targeted therapeutic agents
and immunotherapies. However targeted therapies develop drug resistance within 12 months [1,2] and immunotherapies are only effective in a small proportion of
* Correspondence: e.gray@ecu.edu.au
1
School of Medical Sciences, Edith Cowan University (ECU), 270 Joondalup
Drive, Joondalup, Perth, WA 6027, Australia
Full list of author information is available at the end of the article

patients [3]. Early prediction of treatment failure and the
ability to detect recurrence after treatment would allow
patients who fail on one therapy to be switched early to
different modalities, reducing disease progression and the
cost of a futile therapy.
The presence of circulating tumour cells (CTCs) has
been identified as an independent prognostic marker in
a number of metastatic cancers [4-9]. The number of
CTCs prior to initiation, during and after therapy has
been shown to be indicative of the length of progression
free survival (PFS) and of overall survival (OS) [4,10,11].
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Temporal monitoring of CTC numbers during and after
therapy showed that a decrease in CTCs correlated reasonably well with the clinical course of disease and also
appears useful for evaluating the patient’s response to
therapy [4,8,12,13]. Moreover the predictive value for
survival based on CTC enumeration has been shown to
be superior to standard monitoring tests such as prostatespecific antigen (PSA) in castration-resistant prostate cancer [4] and tumour imaging in metastatic breast cancer
[14]. While most clinical studies, so far, have focused on
CTC enumeration in guiding prognosis in metastatic cancer patients, current research is exploring the pharmacodynamic and predictive biomarker utility of CTCs [15].
For melanoma, relatively few studies have detailed the
prognostic value of CTCs. Two studies have shown that
the number of CTCs is prognostic of OS, with more
than 2 CTCs per 7.5 ml of blood associated with shorter
survival [6,16]. These two studies made use of the CellSearch Melanoma Kit which captures melanoma cell adhesion molecule (MCAM)-expressing cells and detects
melanoma chondroitin sulfate proteoglycan (MCSP)-positive cells as CTCs [16]. However, melanoma tumours have
highly heterogeneous expression patterns [17] and it is
likely their derived CTCs also exhibit this heterogeneity.
Thus in a previous study we undertook a novel strategy by
targeting a combination of melanoma associated antigens,
MCSP and MCAM and previously described stem-cell
markers, ATP-binding cassette sub-family B member
(ABCB5) [18] and CD271 [19], to enrich CTCs. This approach allowed for a more efficient capture of heterogeneous melanoma CTCs relative to targeting a single
marker [20]. Using this multimarker approach, we previously demonstrated that patients at later clinical disease
stages have significantly greater numbers of CTCs than
those at earlier stages [20]. In the present study we use
our multimarker immunomagnetic enrichment method to
evaluate the prognostic value of detecting heterogeneous
CTCs and to investigate whether changes in CTC levels
during therapy correlate with survival outcomes as well
as treatment response as measured by radiographic Response Evaluation Criteria in Solid Tumours (RECIST),
version 1.1 [21].

Methods
Study design

A prospective study was conducted at the Sir Charles
Gardner Hospital (SCGH), Perth, Western Australia.
Patients were enrolled in the study prior to treatment
initiation. Treatment included surgery, standard chemotherapy with dacarbazine, targeted agents including
BRAFV600E inhibitors either alone (vemurafenib) or in
combination with a MEK inhibitor (dabrafenib/trametinib), as well as immunotherapy (ipilimumab). Written
informed consent was obtained from all patients. The
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study was approved by the Human Research Ethics
Committees of Edith Cowan University (No. 2932) and
Sir Charles Gairdner Hospital (No. 2007-123).
Patient follow up

Patients underwent baseline assessment of medical history, physical examination, and radiographic tumour assessment with computer tomography (CT) or positron
emission tomography (PET) scan. Patients were treated
at the discretion of their treating oncologist as appropriate for their disease stage, mutational status and performance status. Patients underwent clinical assessment
at least monthly, including a physical examination and assessment of biochemical parameters. Tumour responses
were assessed radiologically at two to three monthly intervals. CT scans were assessed by RECIST 1.1 criteria
and classified as having a complete response (CR), partial response (PR), stable disease (SD) or progressive
disease (PD).
CTC enumeration

CTC counts were performed at baseline, before the initiation of therapy, and throughout therapy. Patient peripheral blood samples were collected in 4 ml EDTA tubes,
stored at 4°C, and processed within 24 hours of collection. CTCs were enriched and enumerated as previously
described [20]. In summary, whole blood was treated
with red blood cell lysing buffer and remaining cells
were incubated with immunomagnetic beads coated with
antibodies against MCSP, MCAM, ABCB5 and CD271
cell surface antigens to target CTCs. The resulting CTC
enriched fraction was washed to remove non-specifically
bound leukocytes, fixed with 4% paraformaldehyde and
stained with anti-CD45 antibody, followed by an AF488
conjugated secondary antibody (Abcam, Cambridge, MA)
and mounted with media containing DAPI for nuclear
staining. Cells were quantified by microscopy where CTCs
were defined as bead bound cells with a DAPI stained nucleus that were negative for CD45 expression.
Statistics

Association of baseline CTC number and individual
clinical, biochemical and genetic factors were compared
using χ2 test. PFS time was calculated from baseline date
to the date of first reported PD. OS time was calculated
from baseline date to the date of death. Response time
was calculated from the date at baseline to the date of
first reported PR or CR. CTC number at baseline or the
change in CTC number after commencement of treatment, was subject to univariate Cox proportional hazards
regression analysis for association with PFS, OS and response to treatment. Results were analysed in SPSS 21.0
and GraphPad Prism 5.
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Results

Analysis of baseline CTC enumeration

Patient demographics

Of the 27 patients enrolled in the study, 22 were sampled at baseline, prior to treatment. For the other 5 individuals, blood collection started after commencement of
treatment, and they were therefore not included in the
baseline CTC analysis.
We have previously reported that one cell defined as a
CTC may on occasion be found in 4 ml of blood from
healthy individuals; hence here we included only those
patients with 2 or more CTCs in 4 ml of blood. We
found a median of 4 (range 0-10) CTCs at baseline, with
17 patients (72%) presenting with 2 or more CTCs.
A Kaplan-Meier analysis was performed to determine
the association between baseline CTCs and prognostic
values such as OS, PFS and response to treatment
(Figure 1A, B and C). Log-rank test did not show an association between the number of baseline CTCs and
any of these three outcome measurements. The analysis
was performed repeatedly using different cut off values
to define a favourable or unfavourable CTC number, at
3, 4 or 5 CTCs, but no statistical significance was found
in any of these comparisons.
The study participants had undergone a variety of treatments, which have different response rates and mechanisms of action. These different treatments may have
distinct effects on disease progression therefore altering
the predictive value of baseline CTC numbers. Thus, we
performed further analyses focusing on the vemurafenib
treated patients only, given that they were a substantial
group of the study subjects for which a baseline CTC
count was obtained, 10 of 22 (45%). Once again, no predictive value was found between baseline CTCs and OS or
PFS in this subgroup (Figure 1D and E). However, we
found that vemurafenib treated patients with detectable
CTCs (≥2) at baseline took longer to respond to treatment
than those with <2 CTCs (HR 0.11, 95% CI 0.012-0.93,
log-rank P = 0.0437) (Figure 1F). As above, the same analysis was performed for different cut-off values with a 2
CTC cut-off showing the best predictive value.

A total of 27 patients with metastatic cutaneous melanoma were enrolled in the study between September
2011 and January 2013 (Table 1). At the time of
analysis, November 2013, 20 (74%) had experienced
disease progression and 12 (44%) had died, resulting
in a median PFS time of 32 weeks (8 months) and a
median OS time of 53 weeks (12 months). The average length of follow up of patients was 53 weeks
(range, 5-117 weeks).

Table 1 Baseline demographic and clinical characteristics
of patients
Characteristic
Number of patients

Number
N = 27

%

Age at enrolment (years)
Median

59

Range

23-80

Gender
Male

15

56%

Female

12

44%

4

15%

M1b

4

15%

M1c

19

70%

Stage of disease at baseline
Stage IV
M1a

Period of time with metastases
Median

2.5 months

Range

0-115 months

LDH
Normal (≤333)

14

54%

High (>333)

4

15%

Unknown

9

35%

WT

9

35%

V600E

11

42%

V600K

5

19%

K601E

1

4%

unknown

1

4%

Vemurafenib

12

46%

Ipilimumab

4

15%

Dacarbazine

5

19%

Surgery

4

15%

Dabrafenib/Trametinib

1

4%

No treatment

1

4%

BRAF mutation

Treatment (post enrolment)

Changes in CTCs as predictive of OS and response to
treatment

Next we evaluated whether changes in the number of
detected CTCs after treatment initiation is predictive of
patient response to treatment and disease progression.
We collated CTC counts during the first 12 weeks after
treatment initiation in 13 out of the 22 patients with
baseline counts. Of those, 8 were treated with vemurafenib, 3 with ipilimumab and 2 with dacarbazine. The slope
of a linear regression curve was calculated for each patient, including at least three time points and two CTC
counts per time point. The slope of the curve was used as
an indicator of CTC changes during this period; with a
positive slope indicating an increase or no change in
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Figure 1 Kaplan-Meier curves for (A, D) OS, (B, E) PFS and (C, F) time to response of all melanoma patients with > =2 cells and <2 CTCs
in 4.5 ml of blood. (C) Only patients undergoing system therapies were analysed for treatment response, N = 17. Patients treated with the B-Raf
inhibitor vemurafenib were analysed separately (D, E and F).

Figure 2 Prognostic significance of CTC number. Kaplan-Meier curves for (A, D) OS, (B, E) PFS and (C, F) time to response of all melanoma
patients with a positive and negative change in CTC number after treatment, calculated as the slope of plotted CTC counts over the first 12 weeks.
Patients treated with the B-Raf inhibitor vemurafenib were analysed separately (D, E and F).
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Figure 3 Times to response, progression and death among the
27 patients in the study. For patients where the changes in CTC
numbers were evaluated, the bars were coloured red for an increase
or grey for a decrease.

CTC numbers and a negative slope indicating a decrease in CTCs.
Log-rank Mantel-Cox tests (Figure 2A, B and C) demonstrated that a decrease in CTCs after treatment (negative
slope) is associated with longer OS (HR 7.7, 95% CI 1.636.8, log-rank P = 0.0099) and shorter time to respond to
treatment (HR 0.19, 95% CI 0.04-0.93, log-rank P = 0.0406).
No association was observed between changes in CTCs
and PFS (P = 0.3508). A sub-analysis of only vemurafenib
treated patients produced similar results (Figure 2D, E
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and F). A decrease in CTCs in patients treated with
vemurafenib was associated with longer OS (HR 12.7,
95% CI 1.2-135.5, log-rank P = 0.0348). Of note, none of
the vemurafenib treated patients with a decrease in
CTCs died during the follow up period (Figure 3). Moreover, patients with a decrease in CTCs had a faster response to treatment (HR 0.12, 95% CI 0.02-0.86, log-rank
P = 0.0344). All vemurafenib treated patients with a decrease in CTCs had a documented objective response
within the first 12 weeks after treatment. Data from a representative patient is shown in Figure 4, illustrating the
concomitant reduction in metastatic growth and the
number of CTCs after 2 months of treatment with
vemurafenib.

Discussion
The detection of two or more CTCs in 7.5 ml of blood
from metastatic melanoma patients using the CellSearch
system has been found to be prognostic of overall survival
[6,16]. The CellSearch melanoma kit identifies MCAM/
MCSP double positive, CD45/CD34 negative cells as CTCs.
For our study, we implemented a multi-marker antibody
panel for CTC enrichment which, as previously demonstrated, results in detection of more CTCs than when a
single marker is targeted [20]. Using this multi-marker approach we show here that a decrease in CTCs after therapy
initiation is associated with response to treatment and prolonged OS in vemurafenib treated patients.

Figure 4 Therapy response in a metastatic melanoma patient treated with vemurafenib. (A) Representative images of the PET scans
before and during vemurafenib treatment. The arrow indicates lymph node metastasis detected prior to treatment and a complete metabolic
response 2 months after treatment. (B) Reduction in the number of CTCs in 4 ml of whole blood in the same patient. A total of 12 ml of blood
was collected at each time point, 3 × 4 ml tubes. The graph illustrates the number of CTCs found in each of the three blood samples and the
median for each time point.
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In our study, baseline CTC number (prior to treatment)
was not prognostic of OS nor of disease free survival,
which contrasts with results reported by Khoja et al. [6].
The frequency of patients with 2 or more CTCs was similar between studies with around 1 in 4 patients defined as
CTC positive. Although our sample size was relatively
small and perhaps not sufficiently powered to detect limited difference in frequencies, we did not detect even a
trend towards an association between the presence of
CTCs and OS. We observed that our patients in general
had a longer OS with a median of 53 weeks (12 months),
compared to a maximum of 7.2 months for the ≥2 CTCs
group reported by Khoja et al. It is possible that this discrepancy might be because 62% our patients were treated
with more effective therapies (BRAF inhibitors and ipilimumab) compared to 27% in their study.
Interestingly, we observed that patients treated with
vemurafenib with <2 CTCs at baseline rapidly responded
to treatment. However it is unclear why this rapid treatment response did not translate into a longer PFS and
OS. In the BRIM3 study, vemurafenib was effective at
suppressing disease progression leading to death in the
early phase (on average 97 days), however, after a short
period this effect ended and patients reverted to the
pattern of mortality risk observed in individuals treated
with dacarbazine [2]. Furthermore, Sosman et al. observed that although most responses to vemurafenib are
rapid, a proportion of patients (11%) had a delayed
response more than 6 months later accompanied by
longer PFS and OS [22]. This contrasting effect where
delayed responses result in longer survival may explain
why we did not observe an association with OS despite
the association between low baseline CTC count and
rapid response to vemurafenib.
A key finding in our study is the relationship between
changes in CTCs during treatment and patient OS. We
observed a decrease in CTC numbers in 46% of patients
following initiation of treatment and this reduction was
strongly associated with survival time (HR 7.7, CI 1.636.8, log-rank P = 0.0099). This association was still significant when only vemurafenib treated patients were analysed
(P = 0.0348). To a lesser extent, a decrease in CTCs was
also associated with response to treatment (P = 0.0406),
predominantly in the vemurafenib group (P = 0.0344).
This is the first time that changes in CTC number
have been shown to be prognostic of OS and treatment
response in melanoma patients and provides initial data
to support larger studies to evaluate the prognostic value
of CTCs and the effect of different therapies on the
number of CTCs in patients with metastatic melanoma.
An added benefit of our method is that it enriched for
a variety of melanoma CTCs; while it targets those detected by the CellSearch Kit (MCSP and MCAM positive),
it also targets CTCs expressing melanoma initiating cell
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markers (ABCB5 and CD271), which might be excluded
by other methods. Further studies on the dynamics of each
of these cell types, particularly in response to treatment
are important and currently underway in our laboratory.

Conclusion
Measuring pharmacodynamic changes in CTC numbers during treatment is useful for monitoring therapy
response in melanoma patients and for providing
prognostic information relating to OS. Further studies
with larger sample sizes are required to confirm these
observations.
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